IRIS
SERVETTO, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.785
NA - Nord America 2.164
EU - Europa 2.040
SA - Sud America 291
Continente sconosciuto - Info sul continente non disponibili 159
AF - Africa 69
OC - Oceania 4
Totale 7.512
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.051
SG - Singapore 1.070
RU - Federazione Russa 797
IT - Italia 702
CN - Cina 611
VN - Vietnam 510
BR - Brasile 227
HK - Hong Kong 192
DE - Germania 158
IN - India 98
BD - Bangladesh 83
FR - Francia 81
FI - Finlandia 76
CA - Canada 68
JP - Giappone 61
NL - Olanda 56
GB - Regno Unito 45
KR - Corea 42
AR - Argentina 30
CI - Costa d'Avorio 27
PL - Polonia 23
UA - Ucraina 20
ZA - Sudafrica 19
IE - Irlanda 17
PK - Pakistan 17
ID - Indonesia 15
MX - Messico 15
PH - Filippine 13
ES - Italia 12
EC - Ecuador 10
IQ - Iraq 10
SE - Svezia 10
TH - Thailandia 10
LT - Lituania 9
UZ - Uzbekistan 9
MY - Malesia 8
CR - Costa Rica 7
TR - Turchia 7
VE - Venezuela 7
BE - Belgio 6
CO - Colombia 6
IL - Israele 6
AT - Austria 5
EG - Egitto 5
JM - Giamaica 5
TN - Tunisia 5
CL - Cile 4
CZ - Repubblica Ceca 4
HN - Honduras 4
PY - Paraguay 4
SA - Arabia Saudita 4
DZ - Algeria 3
GR - Grecia 3
IR - Iran 3
NI - Nicaragua 3
RS - Serbia 3
AU - Australia 2
AZ - Azerbaigian 2
BG - Bulgaria 2
BO - Bolivia 2
BS - Bahamas 2
EE - Estonia 2
GT - Guatemala 2
KE - Kenya 2
MA - Marocco 2
PT - Portogallo 2
RO - Romania 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AO - Angola 1
BF - Burkina Faso 1
CG - Congo 1
CH - Svizzera 1
CY - Cipro 1
ET - Etiopia 1
GY - Guiana 1
HU - Ungheria 1
KN - Saint Kitts e Nevis 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PG - Papua Nuova Guinea 1
PR - Porto Rico 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TW - Taiwan 1
YE - Yemen 1
YT - Mayotte 1
Totale 7.354
Salva come PNG Salva come JPEG
Città #
Singapore 542
San Jose 378
Ashburn 231
Naples 230
Hefei 214
Moscow 188
Hong Kong 177
Ho Chi Minh City 163
Beijing 153
Hanoi 101
Dallas 94
Santa Clara 92
Chandler 90
Council Bluffs 87
Munich 79
The Dalles 56
Tokyo 55
Lauterbourg 49
Napoli 48
Los Angeles 47
New York 46
Kochi 45
Turku 42
Amsterdam 38
Rome 37
Seoul 37
São Paulo 33
Da Nang 27
Buffalo 26
Toronto 26
Redondo Beach 25
Millbury 24
Boston 23
Haiphong 23
Milan 21
Helsinki 20
Phoenix 20
Chicago 19
Brooklyn 18
Frankfurt am Main 18
Des Moines 16
Falkenstein 16
Lawrence 16
Seattle 16
Warsaw 16
Orem 15
London 14
Montreal 14
Pune 13
Nuremberg 12
Turin 12
Formia 11
Johannesburg 11
Mexico City 11
Houston 10
Nanjing 10
Princeton 10
Shanghai 10
Atlanta 9
Charlotte 9
Chennai 9
Hicksville 9
Ninh Bình 9
Pozzuoli 9
Guayaquil 8
Hải Dương 8
San Mateo 8
Stockholm 8
Tashkent 8
Belo Horizonte 7
Genoa 7
Modica 7
Ottawa 7
Poplar 7
Afragola 6
Biên Hòa 6
Can Tho 6
Kuala Lumpur 6
Lappeenranta 6
Nanchang 6
Wilmington 6
Baghdad 5
Boardman 5
Bologna 5
Changsha 5
Denver 5
Düsseldorf 5
Huế 5
Islamabad 5
Kingston 5
Lahore 5
Long Xuyen 5
Maceió 5
Philadelphia 5
Quảng Ngãi 5
Quận Ba 5
Salvador 5
San José 5
Woodbridge 5
Angri 4
Totale 4.140
Salva come PNG Salva come JPEG
Nome #
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors 217
Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors 172
DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative review 171
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex 171
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 170
1599P - Effects of Hedgehog signaling inhibition on epithelial-stromal interactions in triple negative breast cancer cells 168
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status 168
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 166
C-Src and EGFR inhibition in molecular cancer therapy: What else can we improve? 163
Tumour microenvironment and immune evasion in EGFR addicted NSCLC: Hurdles and possibilities 162
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 157
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study 155
Early assessment of IL8 and PD1+ Treg predicts response and guides treatment monitoring in cemiplimab-treated cutaneous squamous cell carcinoma 153
Mechanisms of resistance to mTOR inhibitors 150
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. 146
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 146
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 143
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges 143
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review 143
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study 142
KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies 140
P0081 Src inhibitors act through different mechanisms to cooperate with EGFR or MEK inhibitors in NSCLC models sensitive or resistant to erlotinib 140
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers 140
Exploring the interplay between Kaposi's sarcoma and SARS‐CoV‐2 infection: A case series and systematic review 138
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges 138
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 137
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. 137
Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer 135
Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study 135
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells 134
FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study 131
ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors 129
EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 128
RNA-Based Next-Generation Sequencing in Non-Small Cell Lung Cancer patients: data from Campania, Italy 127
Blinded independent central review versus local investigator assessment of PFS in RCTs of immunotherapy in advanced cancers: A systematic review and meta-analysis 127
Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC 125
Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: A case report 122
FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer. 121
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies 119
Case report: Potential role of immunotherapy in thymic malignancies: a unique case of a durable and complete response upon an immune checkpoint inhibitor 118
FGFR1 associates with gene promoters and regulates gene transcription: Implications for endocrine resistance in ER+/FGFR1-amplified breast cancer 110
Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes 107
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers 105
AP1-mediated reprogramming of EGFR expression triggers resistance to BLU-667 and LOXO-292 in RET-rearranged tumors 102
Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review 99
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer 95
Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904) 86
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer 85
Nuclear FGFR1 regulates gene transcription and promotes antiestrogen resistance in ERþ breast cancer 84
Texture Analysis of 68Ga-DOTATOC PET/CT Images for the Prediction of Outcome in Patients with Neuroendocrine Tumors 77
FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors 77
FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer 75
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity 75
Malignant granular cell tumor of chest wall: a case report 70
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer 69
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy 68
Breast-cancer specific comprehensive archive of Patient-Reported Outcome Measures (PROMs) for clinical research and clinical practice in oncology: Results from the PRO4All project 50
Prognostic Value of Tumor Dissemination (Dmax) Derived from Basal 18F-FDG Positron Emission Tomography/Computed Tomography in Patients with Advanced Non-Small-Cell Lung Cancer 47
Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis 33
Circulating innate lymphoid cells and IL-18 as potential immune biomarkers in thymic tumors 22
Impact of relative dose intensity of first-line platinum-based chemotherapy in patients with thymic epithelial tumors: a retrospective study 14
Quality of life results and survival outcomes in trials of immunotherapy in advanced cancers: A systematic review and meta-research study 14
Performance of Control Arms in Trials Leading to FDA Cancer Drug Approvals 13
Censoring in trials testing immunotherapy in advanced cancers: a systematic review and a meta-research study 13
APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer 10
CD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer 10
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 8
Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM) 8
Correlation of ORR and PFS with OS outcomes in phase III trials of immunotherapy in advanced NSCLC: Systematic review and meta-analysis 7
Epigenetic modifiers to enhance the efficacy of immune checkpoint inhibitors for the treatment of melanoma 7
Health-related quality of life assessment in trials testing tyrosine kinase inhibitors or immune checkpoints inhibitors in early-stage NSCLC 7
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry 7
Addition of metformin to anti-PD-1/PD-L1 drugs activates anti-tumor immune response in peripheral immune cells of NSCLC patients 6
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis 6
Evaluating quality of life in thoracic malignancy trials: A scoping review on ESMO-MCBS quality of life checklist adherence and concordance with progression-free and overall survival 6
Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis 4
Novel applications of liquid Biopsy: Comprehensive methodology for circulating biomarker exploration in peripheral blood 3
Predictive role of functional respiratory tests in LUng toxicity in stage III NSCLC treated with chemo-, raDIO- and immuno-therapy: PRELUDIO TRIAL 2
The impact of neoadjuvant chemotherapy relative dose intensity on pathological complete response and survival in muscle-invasive urothelial cancer: A multicentric retrospective study 2
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry 2
Totale 7.512
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.767
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.767
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022178 0 0 8 10 4 9 4 4 32 17 38 52
2022/2023347 35 11 15 9 45 36 14 31 51 42 34 24
2023/2024352 14 34 61 22 17 54 23 36 9 10 47 25
2024/20251.939 51 68 4 79 51 121 192 141 91 239 734 168
2025/20264.048 385 350 497 357 594 176 416 194 476 229 179 195
2026/2027352 157 167 28 0 0 0 0 0 0 0 0 0
Totale 7.512